Birkett Bernard
Known title: Sr VP, CFO & TreasurerCIK: 0001658001
Associated companies
Transaction History
| WST | ▼ Sell | Tax Withholding | 36 | $8K | 2/18/2025 | View on chart |
| WST | ▲ Buy | Option Exercise | 779 | $164K | 2/18/2025 | View on chart |
| WST | ▼ Sell | Tax Withholding | 238 | $50K | 2/18/2025 | View on chart |
| WST | ▲ Buy | Option Exercise | 125 | $26K | 2/18/2025 | View on chart |
| WST | ▲ Buy | Grant | 1,969 | $0 | 2/20/2024 | View on chart |
| WST | ▼ Sell | Open Market | 200 | $74K | 8/2/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 8,450 | $866K | 8/2/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 13,884 | $1.4M | 8/2/2023 | View on chart |
| WST | ▼ Sell | Open Market | 22,134 | $8.2M | 8/2/2023 | View on chart |
| WST | ▲ Buy | Grant | 43 | $14K | 3/1/2023 | View on chart |
| WST | ▲ Buy | Grant | 3,614 | $1.1M | 2/21/2023 | View on chart |
| WST | ▼ Sell | Open Market | 9,359 | $3.2M | 8/2/2022 | View on chart |
| WST | ▼ Sell | Open Market | 1,708 | $584K | 8/2/2022 | View on chart |
| WST | ▼ Sell | Open Market | 2,007 | $688K | 8/2/2022 | View on chart |
| WST | ▼ Sell | Open Market | 1,100 | $378K | 8/2/2022 | View on chart |
| WST | ▼ Sell | Tax Withholding | 946 | $273K | 6/21/2022 | View on chart |
| WST | ▲ Buy | Grant | 4,346 | $1.6M | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally
West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.